Ikarian Capital’s Amylyx Pharmaceuticals AMLX Stock Holding History

Ikarian Capital’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-201,187	Closed	-$760K	–	167
2024 Q4	$760K	Sell	201,187 -73,364	-27%	-$345K	0.1%	119
2024 Q3	$890K	Hold	274,551	–	–	0.12%	101
2024 Q2	$522K	Sell	274,551 -56,900	-17%	-$110K	0.09%	93
2024 Q1	$941K	Sell	331,451 -546,049	-62%	-$7.14M	0.1%	107
2023 Q4	$12.9M	Buy	+877,500	New	+$13.4M	1.21%	25
2023 Q2	–	Sell	-10,000	Closed	-$293K	–	131
2023 Q1	$293K	Buy	+10,000	New	+$347K	0.07%	102
2022 Q3	–	Sell	-246,554	Closed	-$6.15M	–	109
2022 Q2	$4.75M	Sell	246,554 -150,100	-38%	-$1.78M	0.87%	40
2022 Q1	$5.1M	Buy	+396,654	New	+$8.96M	0.67%	41

Other funds holding AMLX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Ikarian Capital's AMLX Position: Q1 2025 in Review

Ikarian Capital sold out of Amylyx Pharmaceuticals (AMLX) in Q1 2025, closing a stake of 201,187 shares — an estimated $760K sold.

Ikarian Capital first reported a position in AMLX in Q1 2022 and held it in 8 quarters. The position peaked at $12.9M in Q4 2023. 136 funds tracked by Wall St. Rank hold AMLX as of Q1 2025.

Ikarian Capital reported no remaining Amylyx Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Ikarian Capital sold 201,187 Amylyx Pharmaceuticals shares in Q1 2025, an estimated $760K.
Ikarian Capital first reported a position in Amylyx Pharmaceuticals in Q1 2022 and held it in 8 quarters.
Ikarian Capital's Amylyx Pharmaceuticals position peaked at $12.9M in Q4 2023.
136 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2025.

Based on Ikarian Capital's 13F filing for Q1 2025, filed 15 May 2025.